Anti-MRSA agent 7
Anti-MRSA agent 7 (Compound 12) is a potent antibacterial agent. Anti-MRSA agent 7 inhibits S. aureus DNA gyrase, E. coli DNA gyrase, S. aureus topo IV and E. coli topo IV with IC50s of 0.185, 0.365, 0.341 and 0.059 μM, respectively.
For research use only. We do not sell to patients.
- CAS No.: 3049205-78-6
- Formula: C22H20BrF2N3O4
- Molecular Weight:508.31
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
IC50 & Target
[1]|
TOPO IV 0.059 μM (IC50, E. coli ) |
TOPO IV 0.341 μM (IC50, S. aureus) |
DNA gyrase 0.185 μM (IC50, S. aureus) |
DNA gyrase 0.365 μM (IC50, E. coli ) |
In Vitro
Anti-MRSA agent 7 (Compound 12) shows a dose-dependent killing efficacy achieving bactericidal effect against planktonic methicillin-resistant S. aureus (ATCC 43300) at 8 × MIC after 8 h of treatment, after which re-growth occurs[1].
Antimicrobial activity of Anti-MRSA agent 7 (Compound 12) against a panel of Gram-positive and Gram-negative bacterial pathogens[1]
| Strain | S. aureus (ATCC 29213) | MRSAQA-12.1 | E. coli N43 (CGSC# 5583) | MRSA QA-11.7 | MRSA QA-11.2 | E. faecalis DRK 057 | E. coli (ATCC 25922) |
| MIC (μM) | 0.03 | 0.03 | 0.06 | 0.06 | 0.124 | 4.07 | 252 |
| Strain | E. coli D22 | A. baumannii | E. coli ESBL QA:11.3 | K. pneumoniae | S. alachua RDK 030c | P. aeruginosa RDK 184 | |
| MIC (μM) | 252 | 252 | >252 | >252 | >252 | >252 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD-1 female mice, MRSA neutropenic mouse thigh infection model[1]
-
Dosage:20 and 40 mg/kg
-
Administration:IP/QID (four times a day) at 2, 8, 14, and 20 h post infection
-
Result:Demonstrated inhibition of bacterial growth in a dose dependent manner.
Chemical Information
-
CAS No. 3049205-78-6
-
Molecular Weight 508.31
-
Formula C22H20BrF2N3O4
-
SMILES
COC1=NC2=C(N=CC=C2OC[C@H]3CC[C@@H](CO3)NC(C4=CC(F)=C(C(F)=C4)Br)=O)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-MRSA agent 7 Related Classifications
HY-149271 Related Classifications
Powered by Bioz